Reata Story

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;'>RP</div>
RETA -- USA Stock  

USD 91.20  0.33  0.36%

Reata Pharma Revenue Per Employee is projected to decrease significantly based on the last few years of reporting. The past year's Revenue Per Employee was at 138,612. The current year PPandE Turnover is expected to grow to 14.09, whereas Net Income Per Employee is forecasted to decline to (1.6 M). As many investors are getting excited about healthcare space, it is fair to go over Reata Pharma. We will cover the possibilities of making Reata Pharma into a steady grower in March. Here I will also expose some primary fundamental factors affecting Reata Pharma's services, and outline how it will impact the outlook for investors this year.
Published over a month ago
View all stories for Reata Pharma | View All Stories
What are the odds of Reata Pharma to slip in March?
Reata Pharma reported the previous year's revenue of 8.5 M. Net Loss for the year was (368.92 M) with loss before overhead, payroll, taxes, and interest of (225.99 M).

How important is Reata Pharma's Liquidity

Reata Pharma financial leverage refers to using borrowed capital as a funding source to finance Reata Pharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Reata Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Reata Pharma's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Reata Pharma, but it might be worth checking our own buy vs. sell analysis

Acquisition by Oliger Christy J of 106 shares of Reata Pharma subject to Rule 16b-3

Legal trades by Reata Pharma insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Reata insider trading alert for grant of stock option (right to buy) by Oliger Christy J, the corporate stakeholder, on 16th of April 2021. This event was filed by Reata Pharmaceuticals Inc with SEC on 2021-04-16. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Detailed Perspective On Reata Pharma

Reata Pharma has a total of 31.07 Million outstanding shares. The majority of Reata Pharma outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Reata Pharma to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Reata Pharma. Please pay attention to any change in the institutional holdings of Reata Pharma as this could imply that something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Breakdown

Retail Investors
23.74%
Institutions
71.49%
Retail Investors23.74
Insiders4.77
Institutions71.49

Reata Pharma is likely finish below $125 in 30 days

Current maximum drawdown is at 19.08. Reata Pharma exhibits very low volatility with skewness of -0.17 and kurtosis of 0.36. However, we advise investors to further study Reata Pharma technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Reata Pharma's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Reata Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Take On Reata Pharma

Whereas some other companies in the biotechnology industry are either recovering or due for a correction, Reata may not be as strong as the others in terms of longer-term growth potentials. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither take up nor drop any shares of Reata Pharma at this time. The Reata Pharma risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Reata Pharma.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Reata Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com